| Compound | SLU-PP-332 |
|---|---|
| Category | ERRγ agonist (small molecule) |
| Class | Metabolic and Mitochondrial Compounds |
| Evidence tier | Preclinical |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
SLU-PP-332 — a errγ agonist (small molecule) — sits in the "Preclinical" tier of this catalog. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
An experimental small molecule activating the estrogen-related receptor gamma (ERRγ), described as an exercise mimetic in animal studies.
Mechanism of Action
By activating ERRγ, the compound engages transcriptional programs of oxidative muscle fiber — the pathway through which endurance training adapts muscle.
Research and Evidence
Mouse studies report improved endurance and fatigue resistance; no human trials.
Safety and Side Effects
No human safety data; small-molecule transcription-factor-pathway activation deserves caution outside trials.
Frequently Asked Questions
What is the evidence tier of SLU-PP-332?
SLU-PP-332 is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is SLU-PP-332 an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for SLU-PP-332?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for SLU-PP-332 studies (none registered). [source]
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.